Concert’s CTP-543 Shows Advantages Over Lilly, Pfizer Candidates For Alopecia

Concert’s deuterated ruxolitinib analog is potentially third in line to market for alopecia areata, behind Lilly’s Olumiant and a Pfizer JAK3 inhibitor, but may be demonstrating a best-in-class profile.